Yahoo!
My Yahoo!
Mail
Sign In
[New User?
Sign Up
]
Finance Home
|
Help
Wednesday, February 10, 2010, 10:52pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares,
Register
FINANCE HOME PAGE
INVESTING
FINANCE NEWS
Enter symbol(s):
Market:
Singapore
US
----------------
Argentina
Australia
Austria
Brazil
Canada - Toronto
Canada - Vancouver
China - Shanghai
China - Shenzhen
Denmark
France
Germany XETRA
Germany - Berlin
Hong Kong
India - Bombay
India - National
Indonesia
Israel
Italy
Korea
Korea - KOSDAQ
Malaysia
Mexico
Netherlands
New Zealand
Norway
Spain
Sweden
Switzerland
Taiwan OTC
Taiwan
Thailand
United Kingdom
Search by Company
|
Alphabetical List
BIOINVENT (BINV.ST)
At 10:30PM SGT:
26.60 SEK
0.20 (0.75%)
MORE ON BINV.ST
Quotes
Summary
Options
Historical Prices
Charts
Basic Chart
Technical Chart
News & Info
Headlines
Company Events
Company
Profile
Key Statistics
SEC Filings
Competitors
Industry
Analyst Coverage
Analyst Opinion
Analyst Estimates
Research Reports
Star Analysts
Ownership
Insider Trans.
Insider Roster
Financials
Income Statement
Balance Sheet
Cash Flow
BIOINVENT
(Stockholm:BINV.ST) Delayed quote data
Last Trade:
26.60 SEK
Trade Time:
10:30PM SGT
Change:
0.20 (0.75%)
Prev Close:
26.80
Open:
26.80
Bid:
26.70
Ask:
26.80
1y Target Est:
N/A
Day's Range:
26.40 - 27.10
52wk Range:
19.40 - 30.50
Volume:
304,757
Avg Vol
(3m)
:
297,159
Market Cap:
N/A
P/E
(ttm)
:
N/A
EPS
(ttm)
:
N/A
Div & Yield:
N/A (N/A%)
1d
5d
3m
6m
1y
2y
5y
max
Use Y! Toolbar to track stocks
Add BINV.ST to Portfolio
Download Data
HEADLINES
Q4 2009 BioInvent International AB Earnings Release - Time Not Supplied
CCBN
(Thu, Jan 28)
BioInvent Announces a Directed New Share Issue of SEK 150 Million
Business Wire
(Thu, Jan 14)
BioInvent Announces a Directed New Share Issue of SEK 150 Million
Business Wire
(Thu, Jan 14)
First Patient Treated in BioInvents Phase I Study of the Drug Candidate BI-505 to Treat Multiple Myeloma
Business Wire
(Mon, Jan 4)
First Patient Treated in BioInvent's Phase I Study of the Drug Candidate BI-505 to Treat Multiple Myeloma
Business Wire
(Mon, Jan 4)
BioInvent Signs Licensing Agreement with Daiichi Sankyo for the Discovery and Development of Therapeutic Antibodies
Business Wire
(Fri, Nov 13)
BioInvent Signs Licensing Agreement with Daiichi Sankyo for the Discovery and Development of Therapeutic Antibodies
Business Wire
(Fri, Nov 13)
More Headlines for BINV.ST...
BUSINESS SUMMARY
No business summary available for BINV.ST.
Add to Portfolio
Email to a Friend
Get
Summary
for Another Symbol:
Singapore
US
----------------
Argentina
Australia
Austria
Brazil
Canada - Toronto
Canada - Vancouver
China - Shanghai
China - Shenzhen
Denmark
France
Germany XETRA
Germany - Berlin
Hong Kong
India - Bombay
India - National
Indonesia
Israel
Italy
Korea
Korea - KOSDAQ
Malaysia
Mexico
Netherlands
New Zealand
Norway
Spain
Sweden
Switzerland
Taiwan OTC
Taiwan
Thailand
United Kingdom
Search by Company
Latest News
Singapore Indices